ES2646628R1 - Molécula de azúcar activa farmacéuticamente y su método de síntesis - Google Patents

Molécula de azúcar activa farmacéuticamente y su método de síntesis Download PDF

Info

Publication number
ES2646628R1
ES2646628R1 ES201790034A ES201790034A ES2646628R1 ES 2646628 R1 ES2646628 R1 ES 2646628R1 ES 201790034 A ES201790034 A ES 201790034A ES 201790034 A ES201790034 A ES 201790034A ES 2646628 R1 ES2646628 R1 ES 2646628R1
Authority
ES
Spain
Prior art keywords
sugar molecule
synthesis method
activated sugar
synthesis
pharmaceutically activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201790034A
Other languages
English (en)
Other versions
ES2646628B1 (es
ES2646628A2 (es
Inventor
Yulong SHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huaian Peaks Biological Science And Tech Co Ltd
Huaian Peaks Biological Science And Technology Co Ltd
Original Assignee
Huaian Peaks Biological Science And Tech Co Ltd
Huaian Peaks Biological Science And Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huaian Peaks Biological Science And Tech Co Ltd, Huaian Peaks Biological Science And Technology Co Ltd filed Critical Huaian Peaks Biological Science And Tech Co Ltd
Publication of ES2646628A2 publication Critical patent/ES2646628A2/es
Publication of ES2646628R1 publication Critical patent/ES2646628R1/es
Application granted granted Critical
Publication of ES2646628B1 publication Critical patent/ES2646628B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Este invento revela una molécula de azúcar activa farmacéuticamente y su método de síntesis, que forma una estructura de formula (I) o (II):#{IMAGEN-01}#La invención de la molécula de azúcar puede ser utilizado para la síntesis de moléculas de azúcar de sulfonación, además, se aplica el mecanismo de patogenicidad de la bacteria en el intestino grueso. Métodos de síntesis que ofrece el invento sencillo, cómodo y fácil de usar, puede utilizarse para sintetizar muchas moléculas de azúcar.
ES201790034A 2015-03-13 2016-03-04 Molécula de azúcar activa farmacéuticamente y su método de síntesis Expired - Fee Related ES2646628B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510109400.0A CN104788512A (zh) 2015-03-13 2015-03-13 一种药物活性糖分子合成在抵抗大肠杆菌中的应用方法
CN201510109400 2015-03-13
PCT/CN2016/075585 WO2016145997A1 (zh) 2015-03-13 2016-03-04 一种药物活性糖分子及其合成方法

Publications (3)

Publication Number Publication Date
ES2646628A2 ES2646628A2 (es) 2017-12-14
ES2646628R1 true ES2646628R1 (es) 2017-12-27
ES2646628B1 ES2646628B1 (es) 2018-10-05

Family

ID=53553742

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201790034A Expired - Fee Related ES2646628B1 (es) 2015-03-13 2016-03-04 Molécula de azúcar activa farmacéuticamente y su método de síntesis

Country Status (3)

Country Link
CN (1) CN104788512A (es)
ES (1) ES2646628B1 (es)
WO (1) WO2016145997A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104788512A (zh) * 2015-03-13 2015-07-22 淮安市匹克斯生物科技有限公司 一种药物活性糖分子合成在抵抗大肠杆菌中的应用方法
CN112480188A (zh) * 2020-11-04 2021-03-12 天津科技大学 唾液酸乳糖糖苷和/或类似物、合成方法及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104788512A (zh) * 2015-03-13 2015-07-22 淮安市匹克斯生物科技有限公司 一种药物活性糖分子合成在抵抗大肠杆菌中的应用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B Sun et al. AN EFFICIENT APPROACH FOR TOTAL SYNTHESIS OF AMINOPROPIL FUNCTIONALIZED GANGLIOSIDE GM1B. Tetrahedron Letters, 2012, Vol. 53, Páginas 5711-5715 esquema 3 página 5713 *
P Pornsuriyasak et al. SYNTHESIS OF CANCER ASSOCIATED GLYCOANTIGENS: STAGE-SPECIFIC EMBRYONIC ANTIGEN 3 (SSEA-3). Carbohydrate Research, 2006, Vol. 341, Páginas 1458-1466 esquema 1 página 1459 *

Also Published As

Publication number Publication date
ES2646628B1 (es) 2018-10-05
ES2646628A2 (es) 2017-12-14
CN104788512A (zh) 2015-07-22
WO2016145997A1 (zh) 2016-09-22

Similar Documents

Publication Publication Date Title
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
CL2016001947A1 (es) Compuestos derivados de dihidropirrolopiridina, inhibidores de ror-gamma (ror); composición farmacéutica; y uso en el tratamiento de asma, enfermedad pulmonar obstructiva crónica, artritis reumatoide, fibrosis quística, psoriasis, epilepsia, alzheimer, entre otras.
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
GT201200161A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
EA201790785A1 (ru) Производные тетрагидроизохинолина
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
AR103680A1 (es) Inhibidores selectivos de bace1
EA201892050A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
SMT201600151B (it) Nuovi composti bisostituiti di 3, 4-diammino-3-ciclobuten-1, 2-dione utili nel trattamento di patologie mediate da chemiochine
JP2016027901A5 (es)
CL2013003563A1 (es) Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma.
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
DOP2019000060A (es) 1–arilnaftiridin–3–carboxamidas 7–sustituidas y su uso
EA201692518A3 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
ES2646628R1 (es) Molécula de azúcar activa farmacéuticamente y su método de síntesis
UY36064A (es) Derivados quirales de ácido ciclopentancarboxílico 2,5-disustituidos y su uso
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
CL2014000489A1 (es) Forma de cristal anhidra de rilapladib, forma 3; composicion farmaceutica que lo comprende; combinacion farmaceutica; su uso en el tratamiento de la enfermedad de alzheimer.
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
DOP2015000290A (es) Benzoxazoles sustituidos
EA201791398A1 (ru) Производные фумагиллола

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2646628

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20181005

FD2A Announcement of lapse in spain

Effective date: 20230726